Subtype-dependent relationship between young age at diagnosis and breast cancer survival

Journal of Clinical Oncology

Volumn 34, Issue 27, 2016, Pages 3308-3314

  Partridge, Ann H ^a   Hughes, Melissa E ^a   Warner, Erica T ^a,b   Ottesen, Rebecca A ^c   Wong, Yu Ning ^e   Edge, Stephen B ^f   Theriault, Richard L ^g   Blayney, Douglas W ^d   Niland, Joyce C ^c   Winer, Eric P ^a   Weeks, Jane C ^a   Tamimi, Rulla M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f BAPTIST CANCER CENTER   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COHORT ANALYSIS; DEMOGRAPHY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LONGITUDINAL STUDY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; SOCIAL STATUS; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CLASSIFICATION; EPIDEMIOLOGY; MORTALITY; ONSET AGE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SOCIOECONOMICS; UNITED STATES;

ADULT; AGE OF ONSET; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84989851852     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.8013     Document Type: Article

References (44)

1. American Cancer Society: Breast Cancer Facts & Figures 2013-2014. Atlanta, GA, American Cancer Society, 2013. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf
2. Narod SA: Breast cancer in young women. Nat Rev Clin Oncol 9:460-470, 2012
3. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
4. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
5. Engstrøm MJ, Opdahl S, Hagen AI, et al: Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 140:463-473, 2013
6. Kennecke H, Yerushalmi R, Woods R, et al: Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277, 2010
7. Voduc KD, Cheang MC, Tyldesley S, et al: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691, 2010
8. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007
9. Burstein HJ, Temin S, Anderson H, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255-2269, 2014
10. Arteaga CL, Sliwkowski MX, Osborne CK, et al: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32, 2011
11. Colleoni M, Rotmensz N, Peruzzotti G, et al: Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17:1497-1503, 2006
12. Ahn SH, Son BH, Kim SW, et al: Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: Nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360-2368, 2007
13. Anders CK, Johnson R, Litton J, et al: Breast cancer before age 40 years. Semin Oncol 36:237-249, 2009
14. Collins LC, Marotti JD, Gelber S, et al: Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 131:1061-1066, 2012
15. Keegan TH, DeRouen MC, Press DJ, et al: Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 14:R55, 2012
16. Azim HA Jr, Michiels S, Bedard PL, et al: Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18:1341-1351, 2012
17. Arvold ND, Taghian AG, Niemierko A, et al: Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29:3885-3891, 2011
18. Partridge AH, Gelber S, Piccart-Gebhart MJ, et al: Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: Results from a herceptin adjuvant trial. J Clin Oncol 31:2692-2698, 2013
19. Blows FM, Driver KE, Schmidt MK, et al: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279, 2010
20. Loibl S, Jackisch C, Gade S, et al: Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 72:96s, 2012 (24, suppl)
21. Loibl S, Jackisch C, Lederer B, et al: Outcome after neoadjuvant chemotherapy in young breast cancer patients: A pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat 152:377-387, 2015
22. Niland JC: NCCN Internet-based data system for the conduct of outcomes research. Oncology (Williston Park) 12(11A):142-146, 1998
23. Niland JC: NCCN outcomes research database: Data collection via the Internet. Oncology (Williston Park) 14(11A):100-103, 2000
24. Partridge AH, Hughes ME, Ottesen RA, et al: The effect of age on delay in diagnosis and stage of breast cancer. Oncologist 17:775-782, 2012
25. Fowble BL, Schultz DJ, Overmoyer B, et al: The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 30:23-33, 1994
26. Azim HA Jr, Partridge AH: Biology of breast cancer in young women. Breast Cancer Res 16:427, 2014
27. Sheridan W, Scott T, Caroline S, et al: Breast cancer in young women: Have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat 147:617-629, 2014
28. Anders CK, Deal AM, Miller CR, et al: The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117:1602-1611, 2011
29. Walshe JM, Denduluri N, Swain SM: Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769-5779, 2006
30. Swain SM, Jeong JH, Geyer CE, Jr, et al: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-2065, 2010
31. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003
32. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128, 2010
33. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537, 2011
34. Huiart L, Bouhnik AD, Rey D, et al: Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? Eur J Cancer 48:1939-1946, 2012
35. Huiart L, Ferdynus C, Giorgi R: A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: Summarizing the data for clinicians. Breast Cancer Res Treat 138:325-328, 2013
36. Pagani O, Regan MM, Walley BA, et al: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107-118, 2014
37. Francis PA, Regan MM, Fleming GF, et al: Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436-446, 2015
38. Greenup R, Buchanan A, Lorizio W, et al: Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20:3254-3258, 2013
39. Wang C, Zhang J, Wang Y, et al: Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Ann Oncol 26:523-528, 2015
40. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007
41. Anders CK, Acharya CR, Hsu DS, et al: Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 3:e1373, 2008
42. Azim HA, Jr., Santoro L, Russell-Edu W, et al: Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies. Cancer Treat Rev 38:834-842, 2012
43. Collins LC, Marotti JD, Baer HJ, et al: Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 100:218-221, 2008
44. Warner ET, Tamimi RM, Hughes ME, et al: Racial and ethnic differences in breast cancer survival: Mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33:2254-2261, 2015